C02 C00-C14
Conditions
Interventions
Group 1: Enhanced blood coagulation monitoring will be performed in participants at begin of surgery and on 7 time points after surgery. Viscoelastic testing (VET) will be performed additional to stan
Sponsors
Universitätsklinikum Carl Gustav CarusKlinik und Poliklinik für Anästhesie und Intensivmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Adult patients above 18 years of age who are undergoing maxillofacial surgery and receive a microsurgical flap treatment. In detail the following cases are selected: cases: Patients who receive microvascular reconstruction as part of tumour surgery - Patients who receive microvascular reconstruction as part of secondary reconstruction - Patients who receive microvascular reconstruction in the context of bone necrosis or osteomyelitis
Exclusion criteria
Exclusion criteria: Patients developing severe coagulation disorder during in-hospital stay (DIC, HIT) Patients with preexisting severe thrombophilia (anti-phospholipid-syndrome, homozygous FV-Leiden mutation, Anti-Thrombin defect) Patients with preexisting severe bleeding disorder (Haemophilia A/B (residual activity <10%) and vWF-Syndrome Type 2B,M,N, 3)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is defined as free flap loss and the occurrence of flap thrombosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are patients survival during in hospital stay and the incidence of any thromboembolic complication. | — |
Countries
Germany
Contacts
Public ContactLars Heubner
Universitätsklinikum Carl Gustav CarusKlinik und Poliklinik für Anästhesie und Intensivmedizin
Outcome results
None listed